Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eragidomide - Celgene Corporation

Drug Profile

Eragidomide - Celgene Corporation

Alternative Names: CC-90009; GSPT1 CELMoD

Latest Information Update: 03 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Class Acetamides; Antineoplastics; Chlorobenzenes; Fluorine compounds; Isoindoles; Piperidines; Small molecules
  • Mechanism of Action CRBN protein modulators; Peptide-chain-release factor 3 modulators; Ubiquitin protein ligase complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Phase I Myelodysplastic syndromes

Most Recent Events

  • 28 Jul 2022 Eragidomide is still in Myelodysplastic syndromes (Second-line therapy or greater) in Canada, France, Norway, Spain, United Kingdom and USA (IV) (NCT02848001)
  • 28 Jul 2022 Eragidomide is still in phase I trials for Acute myeloid leukaemia (Second-line therapy or greater) in Canada, France, Norway, Spain, United Kingdom and USA (IV) (NCT02848001)
  • 28 Apr 2022 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Canada (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top